Skip to main content

Health Stocks in Motion

Incyte surges on a development deal with Pfizer.
  • Author:
  • Publish date:

Updated from 3:02 p.m.

Shares of


(INCY) - Get Free Report

were among the best-performing health-related stocks Monday, jumping 22% after the company signed a research and licensing deal with


(PFE) - Get Free Report


The agreement covers the development and marketing of Incyte's CCR2 antagonists, which are chemicals that help suppress inflammation. Pfizer will gain commercialization rights to the compounds, with Incyte receiving up to $803 million from the pharmaceutical giant. Pfizer will make an upfront payment of $40 million. Incyte also said Pfizer will purchase $20 million in convertible subordinated notes. Shares of Incyte were up $1.06 to $5.86. Shares of Pfizer rose 14 cents to $21.74.

Bentley Pharmaceuticals


rose 13% after the company's Irish subsidiary, Bentley Pharmaceuticals Ireland Ltd, received approval from the Irish Medicines Board to market 10 milligram, 20 mg and 40 mg capsules of generic omeprazole, a proton-pump inhibitor used in the treatment of acid-related gastrointestinal disorder, in Ireland. The specialty pharmaceutical and drug delivery company also said its Spanish subsidiary, Laboratorios Davur, signed a distribution agreement with Irish company Consilient Health Ltd. Under the agreement, Consilient has a non-exclusive right to distribute and commercialize a Davur generic omeprazole in the U.K. Bentley shares gained $2.02 to $17.92.

Shares of

Cubist Pharmaceuticals


rose 2.2% after the company said the Food and Drug Administration accepted its supplemental new drug application for Cubicin and gave the antibiotic priority review status. The priority review gives the FDA a target date to act on the sNDA filing by March 24. The stock finished higher by 50 cents to $23.20.



shares tumbled nearly 11% after the company announced plans for a $65 million private placement. After expenses, the maker of genetic analysis systems expects net proceeds of $61 million. Under the agreement, Solexa will offer 10 million shares of common stock at $6.50 a share, and will issue warrants to purchase 3.5 million shares at $7.50. Almost 3.9 million common shares and 1.3 million warrants will be issued, with the closing expected Tuesday. The rest will be issued in a second closing subject to shareholder approval. Shares closed down $1 to $7.90.

Other health stocks trading actively Monday were



, closed up $3.82 to $31.57;



, finished down $4.79 to $51.31;


(MRK) - Get Free Report

, closed up 5 cents to $30.47;

Schering Plough


closed down 11 cents to $19.60;

Abbott Labs

(ABT) - Get Free Report

, down 53 cents to $40.37; and

Biogen Idec

(BIIB) - Get Free Report

finished down 21 cents to $44.12.